Sputnik V gets DCGI nod but pricing remains issue

Sputnik V gets DCGI nod but pricing remains issue

FPJ BureauUpdated: Tuesday, April 13, 2021, 11:24 PM IST
article-image
Pixabay (File Photo)

Even as the Drugs Controller General of India cleared the Russian Sputnik V vaccine for use in the country, there is still no decision on the price at which the vaccine will be procured by the government.

Price negotiations with the Russian Direct Investment Fund (RDIF) are yet to be concluded, reports NDTV. The rollout of the new vaccine in India is contingent on the successful conclusion of these negotiations and there are clear indicators that RDIF may not be able to match the price of $2 a dose that the government is presently paying for the AstraZeneca vaccine known as Covishield in India.

At the moment, however, the government has firmly rejected the roll-out of any vaccine at commercial rates, repeatedly stressing that the vaccines need to be made available to priority groups identified by the Centre and at prices which it has set.

RECENT STORIES

2017 Corruption Case: CBI Files Closure Report In Corruption Case Against NCP's Praful Patel

2017 Corruption Case: CBI Files Closure Report In Corruption Case Against NCP's Praful Patel

Lok Sabha Elections 2024: Grand Alliance To Declare Seat Sharing Deal Soon

Lok Sabha Elections 2024: Grand Alliance To Declare Seat Sharing Deal Soon

Dissidence Forces Congress Leaders To Cancel Events In Karnataka Districts

Dissidence Forces Congress Leaders To Cancel Events In Karnataka Districts

'This Is Blessing Of Baba Gorakhnath,' Says Ex-BJP MLA's Son On Gangster Mukhtar Ansari's Death

'This Is Blessing Of Baba Gorakhnath,' Says Ex-BJP MLA's Son On Gangster Mukhtar Ansari's Death

'Who Will Buy ₹5k Thing For ₹25cr?' Says Punjab BJP Chief Sunil Jakhar On AAP's Allegations

'Who Will Buy ₹5k Thing For ₹25cr?' Says Punjab BJP Chief Sunil Jakhar On AAP's Allegations